Executive changes at Merck KGaA

1 June 2021

Germany’s Merck KGaA (MRK: DE) is further pushing its science and technology based strategic growth trajectory with two appointments to key senior leadership positions on the group level. In both cases internal candidates will be promoted which underlines the high quality of Merck’s top talent pipeline.

Effective June 1, Roman Werth will become new head of group strategy, M&A and M Ventures, reporting to Belén Garijo, chairman of the executive board and chief executive of Merck.

Isabel de Paoli, currently heading group strategy and transformation, has decided to leave the company to turn to other career opportunities outside of Merck.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK